Literature DB >> 1656865

Antiviral activity of oxetanocins against varicella-zoster virus.

T Sakuma1, M Saijo, T Suzutani, I Yoshida, S Saito, M Kitagawa, S Hasegawa, M Azuma.   

Abstract

Several new nucleosides with an oxetanosyl-N-glycoside group, named oxetanocins, were evaluated for their antiviral activities against varicella-zoster virus (VZV) in human embryo lung cells. 9-(2-deoxy-2-hydroxy-methyl-beta-D-erythro-oxetanosyl)guanine (OXT-G) and 9-(2-deoxy-2-hydroxymethyl-beta-D-erythro-oxetanosyl)-2- aminoadenine were effective against not only thymidine kinase-positive (TK+) VZV (YS strain) but also thymidine kinase-negative (TK-) VZV (YSR strain), whereas carbocyclic OXT-G was effective against TK+ VZV but not against TK- VZV. [3H]OXT-G was incorporated into TK+ VZV-infected cells and TK- VZV-infected cells more than into mock-infected cells and was converted into the triphosphate form.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656865      PMCID: PMC245204          DOI: 10.1128/AAC.35.7.1512

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis.

Authors:  I Votruba; R Bernaerts; T Sakuma; E De Clercq; A Merta; I Rosenberg; A Holý
Journal:  Mol Pharmacol       Date:  1987-10       Impact factor: 4.436

2.  Derivatives of oxetanocin: oxetanocins H, X and G, and 2-aminooxetanocin A.

Authors:  N Shimada; S Hasegawa; S Saito; T Nishikiori; A Fujii; T Takita
Journal:  J Antibiot (Tokyo)       Date:  1987-12       Impact factor: 2.649

3.  Efficacy of oxetanocin G against herpes simplex virus type 2 and murine cytomegalovirus infections in mice.

Authors:  Y Nishiyama; N Yamamoto; Y Yamada; H Fujioka; N Shimada; K Takahashi
Journal:  J Antibiot (Tokyo)       Date:  1989-08       Impact factor: 2.649

4.  Oxetanocin, a novel nucleoside from bacteria.

Authors:  N Shimada; S Hasegawa; T Harada; T Tomisawa; A Fujii; T Takita
Journal:  J Antibiot (Tokyo)       Date:  1986-11       Impact factor: 2.649

5.  Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil.

Authors:  T Sakuma
Journal:  Antimicrob Agents Chemother       Date:  1984-06       Impact factor: 5.191

6.  The complete DNA sequence of varicella-zoster virus.

Authors:  A J Davison; J E Scott
Journal:  J Gen Virol       Date:  1986-09       Impact factor: 3.891

7.  Efficacies of antiherpesvirus nucleosides against two strains of herpes simplex virus type 1 in Vero and human embryo lung fibroblast cells.

Authors:  T Suzutani; H Machida; T Sakuma
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

8.  Selective inhibition of human cytomegalovirus replication by a novel nucleoside, oxetanocin G.

Authors:  Y Nishiyama; N Yamamoto; K Takahash; N Shimada
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

9.  Anti-herpesvirus activity of carbocyclic oxetanocin G in vitro.

Authors:  Y Nishiyama; N Yamamoto; Y Yamada; T Daikoku; Y Ichikawa; K Takahashi
Journal:  J Antibiot (Tokyo)       Date:  1989-12       Impact factor: 2.649

10.  Analysis of mutations in the thymidine kinase genes of drug-resistant varicella-zoster virus populations using the polymerase chain reaction.

Authors:  S F Lacey; T Suzutani; K L Powell; D J Purifoy; R W Honess
Journal:  J Gen Virol       Date:  1991-03       Impact factor: 3.891

  10 in total
  2 in total

1.  Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.

Authors:  G Andrei; R Snoeck; D Reymen; C Liesnard; P Goubau; J Desmyter; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-04       Impact factor: 3.267

Review 2.  Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.

Authors:  R Snoeck; G Andrei; E De Clercq
Journal:  Drugs       Date:  1999-02       Impact factor: 11.431

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.